Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3849345 | 0.69 | — | — | |
| SCHEMBL19035909 | 0.65 | TRPA1 (0.32) | TRPA1 | |
| SCHEMBL29595470 | 0.64 | — | — | |
| SCHEMBL9178868 | 0.64 | — | — | |
| SCHEMBL29633894 | 0.63 | — | — | |
| SCHEMBL15075855 | 0.63 | — | — | |
| SCHEMBL5050147 | 0.63 | TRPA1 (0.58) | TRPA1 | |
| SCHEMBL9926021 | 0.63 | TRPA1 (0.58) | TRPA1 | |
| SCHEMBL30691872 | 0.63 | TRPA1 (0.58) | TRPA1 | |
| SCHEMBL379614 | 0.62 | TRPA1 (0.33) | TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119186638-A | Catalyst for preparing dialkyl carbonate, preparation method and application thereof | 中国石油化工股份有限公司 | 2024-12-27 | — | — | CN | claimed |
| CN-113387885-B | Preparation method of 1-benzazepine compound | 兰州大学 | 2023-01-03 | — | — | CN | claimed |
| CN-113387885-A | Preparation method of 1-benzazepine compound | 兰州大学 | 2021-09-14 | — | — | CN | claimed |
| EP-0119954-B1 | 3-AMINO-1-BENZAZEPIN-2-ONE-1-ALCANOIC ACIDS, PROCESS FOR THEIR PREPARATION, THEIR PHARMACEUTICAL PREPARATION AS WELL AS THEIR THERAPEUTIC USE | CIBA-GEIGY AG (CH) | 1990-03-14 | — | — | EP | claimed |
| US-12624111-B2 | Methods for treating metastatic colon cancer with leronlimab | CYTODYN INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20250224340-A1 | Colorimetric Detection of Organic Amines Using Metal-Organic Frameworks | THE JOHNS HOPKINS UNIVERSITY | 2025-07-10 | — | — | US | disclosed |
| CN-119186638-A | Catalyst for preparing dialkyl carbonate, preparation method and application thereof | 中国石油化工股份有限公司 | 2024-12-27 | — | — | CN | disclosed |
| CN-116891435-A | Method for synthesizing benzazepine derivative | 浙江理工大学 | 2023-10-17 | — | — | CN | disclosed |
| CN-109996807-B | SCN9A antisense oligonucleotides | 奥利通公司 | 2023-07-28 | — | — | CN | disclosed |
| WO-2023284654-A1 | ORGANIC HETEROCYCLIC COMPOUND AND APPLICATION THEREOF IN ORGANIC LIGHT EMITTING DIODE | 浙江光昊光电科技有限公司 | 2023-01-19 | — | — | WO | disclosed |
| CN-113387885-B | Preparation method of 1-benzazepine compound | 兰州大学 | 2023-01-03 | — | — | CN | disclosed |
| CN-113387885-B | Preparation method of 1-benzazepine compound | 兰州大学 | 2023-01-03 | — | — | CN | disclosed |
| US-5747487-A | N-(4-((4,5-DIHYDRO-6H-THIAZOL(5,4-D)(1)BENZAZEPIN-6-YL) -CARBONYL)PHENYL)BENZAMIDES; DISEASES CHARATERIZED BY EXCESS RENAL ABSORPTION OF WATER, E.G. CONGESTIVE HEART DISEASE, HYERTENSION; OXYTOCIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1998-05-05 | — | — | US | disclosed |
| WO-1998002423-A1 | PROCESS FOR PREPARING 1-SUBSTITUTED 4-CYANO-1,2,3-TRIAZOLES | NOVARTIS AG (CH) | 1998-01-22 | — | — | WO | disclosed |
| US-5693635-A | TREATMENT OF DISEASES CHARACTERIZED BY EXCESS RENAL ABSORPTION OF WATER; CONGESTIVE HEART FAILURE, NEPHROTIC SYNDROME | AMERICAN CYANAMID COMPANY (US) | 1997-12-02 | — | — | US | disclosed |
| US-5686445-A | Pyridobenzoxazepine and pyridobenzothiazepine vasopressin antagonists | AMERICAN CYANAMID COMPANY (US) | 1997-11-11 | — | — | US | disclosed |
| EP-0434844-A1 | NEW CYCLIC ANTHRANILIC ACID DERIVATIVE AND METHOD OF PRODUCING THE SAME | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1991-07-03 | — | — | EP | disclosed |
| EP-0130538-A3 | COMPOSITION FOR TREATING ALLERGY | USV PHARMACEUTICAL CORPORATION (US) | 1985-12-04 | — | — | EP | disclosed |
| EP-0130538-A2 | Composition for treating allergy | USV PHARMACEUTICAL CORPORATION (US) | 1985-01-09 | — | — | EP | disclosed |
| EP-0130538-A2 | Composition for treating allergy | USV PHARMACEUTICAL CORPORATION (US) | 1985-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624111-B2 | Methods for treating metastatic colon cancer with leronlimab | CCR5, CCL2, CCR2 | TRPA1 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.